Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT00344422 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Myeloma
M-Protein
Myeloma Proteins

Interventions

DRUG: Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]